Voyager Therapeutics, Inc.
VYGR
$4.15
$0.030.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -45.50% | -49.53% | -80.88% | -70.38% | -43.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.50% | -49.53% | -80.88% | -70.38% | -43.75% |
| Cost of Revenue | -3.06% | 5.93% | 16.75% | 16.28% | 28.41% |
| Gross Profit | -42.53% | -104.83% | -311.29% | -360.07% | -439.79% |
| SG&A Expenses | -5.11% | 1.46% | 0.15% | 0.10% | 4.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.51% | 4.93% | 12.69% | 12.21% | 22.16% |
| Operating Income | -24.80% | -58.87% | -1,311.33% | -2,871.99% | -482.28% |
| Income Before Tax | -38.70% | -85.86% | -570.68% | -1,205.04% | -3,511.56% |
| Income Tax Expenses | -82.41% | -78.35% | -20.38% | -0.59% | -4.18% |
| Earnings from Continuing Operations | -37.72% | -84.18% | -589.88% | -1,296.21% | -2,682.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.72% | -84.18% | -589.88% | -1,296.21% | -2,682.29% |
| EBIT | -24.80% | -58.87% | -1,311.33% | -2,871.99% | -482.28% |
| EBITDA | -26.59% | -63.41% | -918.94% | -16,744.55% | -658.53% |
| EPS Basic | -35.63% | -81.30% | -388.61% | -683.06% | -8,479.41% |
| Normalized Basic EPS | -36.59% | -84.84% | -364.67% | -589.20% | -175,320.00% |
| EPS Diluted | -35.03% | -79.83% | -404.48% | -756.10% | -3,033.05% |
| Normalized Diluted EPS | -36.59% | -84.84% | -375.32% | -633.94% | -4,242.08% |
| Average Basic Shares Outstanding | 1.73% | 1.77% | 7.90% | 14.88% | 23.03% |
| Average Diluted Shares Outstanding | 1.73% | 1.77% | 7.36% | 14.26% | 22.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |